Research Article Details
| Article ID: | A50124 |
| PMID: | 35511653 |
| Source: | Minerva Gastroenterol (Torino) |
| Title: | Treatment with phosphatidylcholine of patients with non-alcoholic fatty liver disease: a prospective pilot study. |
| Abstract: | BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is characterized by a complex clinical picture that includes non-alcoholic steatohepatitis and cirrhosis. In the last decades, several studies have shown that NAFLD increases the risk of cardiovascular diseases. In a prospective pilot study, the benefit of treatment with phosphatidylcoline in NAFLD patients has been assessed. METHODS: Thirty patients with NAFLD were enrolled. All received treatment with phosphatidylcoline (Essentiale® Forte N) 300 mg capsules, administered 2 at time orally, 3 times a day with meals for three months. The clinical and laboratory parameters before and after treatment were compared. RESULTS: After the administration of Essentiale® Forte N the level of alanine aminotransferase (ALT) decreased by 59.6% (p<0.05) and that of aspartate transaminase (AST) decreased by 75.4% (p<0.05). Moreover, after treatment, an increase in antioxidant enzymes superoxide dismutase by 48% (p<0.05) and glutathione peroxidase by 48.1% (p<0.05) was observed. CONCLUSIONS: The results of the study indicate that treatment with Essentiale® Forte N for 3 months was associated with a significant decrease in transaminase levels, in the activity of lipid peroxidation markers and an increase in the level of antioxidant enzymes. |
| DOI: | 10.23736/S2724-5985.21.03066-7 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D075 | Choline | Supplement | DB00122 | PLD2 product of; PLD1 product of | -- | Under clinical trials | Details |
| D273 | Phosphatidylcholine | Chemical drug | DB15834 | -- | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| D158 | Glutathione | Chemical drug | DB00143 | MGST3; HPGDS; GSTM2; GSTM5; GPX7 cofactor; MGST2; GSS; GSTM1; GSTK1; GSTM3; GSTM4; GPX1 cofactor; GPX2 cofactor; GPX3 cofactor | -- | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |